MEDP
HealthcareMedpace Holdings, Inc. · Medical - Diagnostics & Research · $12B
What is Medpace Holdings, Inc.?
Medpace Holdings is a full-service contract research organization (CRO) headquartered in Cincinnati, Ohio, supporting drug and medical device development across North America, Europe, and Asia.
Medpace partners with pharmaceutical, biotechnology, and medical device companies to manage clinical trials from Phase I through Phase IV. Revenue comes from service contracts covering project management, regulatory affairs, data analysis, clinical monitoring, and laboratory support — essentially acting as an outsourced clinical development team for its clients.
The company traces its operational roots to 1992 and is based in Cincinnati, Ohio.
- Phase I–IV clinical trial management
- Regulatory affairs and new drug application support
- Central laboratory and bio-analytical services
- Pharmacovigilance and post-marketing support
Is MEDP a Good Stock to Buy?
UQS Score rates MEDP as Good overall, reflecting a balanced profile across the five quality pillars.
The Quality pillar stands out as the clearest strength, suggesting Medpace generates reliable returns relative to its asset base. The Growth pillar also earns a Good rating, consistent with steady demand for outsourced clinical research services.
Moat and Risk both land at Neutral, indicating the competitive positioning and risk profile are in line with sector peers rather than exceptional.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MEDP pay dividends?
No — Medpace Holdings, Inc. does not currently pay a dividend.
Medpace does not currently pay a dividend. As a growth-oriented CRO, the company reinvests capital into expanding its clinical service capabilities and geographic reach rather than returning cash to shareholders through distributions.
When does MEDP report earnings?
Medpace Holdings reports earnings on a quarterly cadence, typical for US-listed equities.
Demand for outsourced clinical development has remained a tailwind for the CRO sector broadly. Medpace's Quality pillar rating suggests the business has maintained consistent operational performance, though results can vary with client pipeline activity and trial timing.
For the most recent quarter's results, visit Medpace Holdings' investor relations page directly.
MEDP Price History
+208.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Medpace Holdings, Inc.?
Based on Medpace Holdings, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Medpace Holdings do?
Medpace is a contract research organization that manages clinical trials on behalf of pharmaceutical, biotech, and medical device companies. Its services span the full development lifecycle — from early-phase human pharmacology studies through post-marketing support — allowing clients to outsource complex regulatory and scientific work.
Does MEDP pay dividends?
No, Medpace does not pay a dividend. The company focuses on reinvesting in its clinical service platform and expanding its therapeutic expertise rather than distributing cash to shareholders.
When does MEDP report earnings?
Medpace reports on a standard quarterly schedule. Because specific dates can shift, check the company's investor relations page or your brokerage for the confirmed release date before each quarter.
Is MEDP a good stock to buy?
UQS Score rates MEDP as Good, with a notably Strong Quality pillar. Whether it fits your portfolio depends on your goals and risk tolerance. The full pillar breakdown — available to Pro members — gives a more complete picture of where the stock stands.
Is MEDP overvalued?
The UQS Valuation pillar for MEDP is rated Neutral, suggesting the market is pricing the stock in line with its fundamentals rather than at a significant premium or discount. Pro members can view the underlying valuation metrics in detail.
What is MEDP's market cap bracket?
Medpace Holdings is classified as a large-cap company, placing it among the more established players in the contract research organization space.
Is MEDP a long-term quality indicator?
The UQS framework evaluates long-term quality through five pillars. MEDP's Strong Quality rating and Good Growth rating suggest a business with durable operational characteristics, though the Neutral Moat rating is worth monitoring for investors with a long time horizon.
What sector does MEDP belong to?
Medpace operates in the Healthcare sector, specifically within clinical research and contract development services — a segment that benefits from ongoing pharmaceutical and biotech R&D spending.
Unlock Full MEDP Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare MEDP against sector peers on a standardized scoring framework
- ✓Track score changes over time as new data is released
Pro Analysis
MEDP — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 61.3 | 88.0 | 42.0 | 58.4 | 62.1 | 52.0 | -0.4 |
| May 16, 2026 | 61.7 | 88.5 | 42.0 | 58.4 | 62.1 | 53.7 | +0.2 |
| May 11, 2026 | 61.5 | 88.4 | 42.0 | 58.4 | 62.1 | 53.0 | +1.3 |
| May 7, 2026 | 60.2 | 86.1 | 42.0 | 58.4 | 57.6 | 52.5 | -0.2 |
| May 3, 2026 | 60.4 | 86.1 | 42.0 | 58.4 | 57.6 | 53.5 | -0.1 |
| May 1, 2026 | 60.5 | 86.1 | 42.0 | 58.4 | 57.6 | 54.1 | -0.2 |
| Apr 26, 2026 | 60.7 | 86.1 | 42.0 | 59.4 | 57.6 | 54.6 | +1.2 |
| Apr 25, 2026 | 59.5 | 86.1 | 42.0 | 59.4 | 57.6 | 46.3 | -1.5 |
| Apr 24, 2026 | 61.0 | 86.1 | 42.0 | 65.0 | 57.6 | 48.9 | -0.1 |
| Apr 22, 2026 | 61.1 | 86.1 | 42.0 | 65.4 | 57.6 | 49.1 | 0.0 |
MEDP — Pillar Breakdown
Quality
— 88.0/100 (25%)Medpace Holdings, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 58.4/100 (20%)Medpace Holdings, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 62.1/100 (15%)Medpace Holdings, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 52.0/100 (15%)Medpace Holdings, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Medpace Holdings, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MEDP.
Score Composition
Financial Data
More Stock Analysis
How is the MEDP UQS Score Calculated?
The UQS (Unified Quality Score) for Medpace Holdings, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Medpace Holdings, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Medpace Holdings, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.